On March 6, 2018 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, reported that the company will present at the Cowen and Company 38th Annual Health Care Conference 2018 in Boston, Massachusetts (Press release, Constellation Pharmaceuticals, MAR 6, 2018, View Source [SID1234524412]). The presentation is scheduled for Tuesday, March 13, at 11:20 a.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available live and 30 days following the event. The webcast may be accessed via the conference website and from the investor relations section of the Corvus website

On March 6, 2018 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, reported that the company will present at the Cowen and Company 38th Annual Health Care Conference 2018 in Boston, Massachusetts (Press release, Corvus Pharmaceuticals, MAR 6, 2018, View Source;p=RssLanding&cat=news&id=2336475 [SID1234524442]). The presentation is scheduled for Tuesday, March 13, at 11:20 a.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available live and 30 days following the event. The webcast may be accessed via the conference website and from the investor relations section of the Corvus website.

On March 6, 2018 Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) reported that Bill Lis, chief executive officer, will present at the following conferences in March (Press release, Portola Pharmaceuticals, MAR 6, 2018, View Source;p=RssLanding&cat=news&id=2336594 [SID1234524461]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen and Company’s 38th Annual Health Care Conference on Tuesday, March 13, 2018, at 8:40 a.m. Eastern Time in Boston.
Oppenheimer’s 28th Annual Healthcare Conference on Tuesday, March 20, 2018, at 10:55 a.m. Eastern Time in New York.
Both presentations will be webcast live and available for replay from Portola’s website at www.portola.com in the Investor Relations section.

Rigel has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Rigel, 2018, MAR 6, 2018, View Source [SID1234524473]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On march 6, 2018 CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, reported that it will host a conference call and live audio webcast on Thursday, March 15, 2018 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2017 and to provide a business update (Press release, CymaBay Therapeutics, MAR 6, 2018, View Source [SID1234524443]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Details
To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13676717. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company’s website at View Source